{Reference Type}: Journal Article
{Title}: Geographic and economic influences on benralizumab prescribing for severe asthma in Japan.
{Author}: Kobayashi N;Matsumoto H;Somekawa K;Kaneko A;Fukuda N;Muraoka S;Ohtsu Y;Hirata M;Nagasawa R;Kubo S;Murohashi K;Fujii H;Aoki A;Watanabe K;Horita N;Hara Y;Kaneko T;
{Journal}: Sci Rep
{Volume}: 14
{Issue}: 1
{Year}: 2024 07 2
{Factor}: 4.996
{DOI}: 10.1038/s41598-024-65407-4
{Abstract}: Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential prescribing and access. This study aimed to quantify regional prescribing variations for benralizumab nationwide. Using Japan's National Database (NDB) of insurance claims (2009-2019), benralizumab standardized claim ratios (SCRs) were calculated for 47 prefectures. Correlations between SCRs and other biologics' SCRs, economic variables like average income, and physician densities were evaluated through univariate analysis and multivariate regressions. Income-related barriers to optimal prescribing were examined. Wide variation emerged in benralizumab SCRs, from 40.1 to 184.2 across prefectures. SCRs strongly correlated with omalizumab (r = 0.61, p < 0.00001) and mepolizumab (r = 0.43, p = 0.0024). Average monthly income also positively correlated with benralizumab SCRs (r = 0.45, p = 0.0016), whereas lifestyle factors were insignificant. Respiratory specialist density modestly correlated with SCRs (r = 0.29, p = 0.047). In multivariate regressions, average income remained the most robust predictor (B = 0.74, p = 0.022). Benralizumab SCRs strongly associate with income metrics more than healthcare infrastructure/population factors. Many regions show low SCRs, constituting apparent prescribing gaps. Access barriers for advanced asthma therapies remain inequitable among Japan's income strata. Addressing affordability alongside specialist allocation can achieve better prescribing quality and asthma outcomes.